Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.

Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research12 Jan 2004Cited by 114 (Europe PMC)

PMID15005850DOI10.1359/jbmr.040112PepBankPUB-15005850

Publisher page PubMedAsk about this study

Jump to 26 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study26

26 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, teriparatide restored femoral neck trabecular bone volume to sham levels.
In plain wordsIn monkeys with removed ovaries, teriparatide restored spongy bone volume to sham control levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck trabecular bone volume
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Sham vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
The femoral neck showed significant reduction in trabecular bone volume (BV/TV) for OVX compared with sham, whereas PTH1 BV/TV was restored to sham levels and PTH5 BV/TV was greater than sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585001
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, high-dose teriparatide produced greater femoral neck trabecular bone volume than sham controls.
In plain wordsIn monkeys with removed ovaries, high-dose teriparatide increased spongy bone volume above sham control levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck trabecular bone volume
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Sham vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
The femoral neck showed significant reduction in trabecular bone volume (BV/TV) for OVX compared with sham, whereas PTH1 BV/TV was restored to sham levels and PTH5 BV/TV was greater than sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585002
03AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, high-dose teriparatide increased femoral neck trabecular bone volume versus OVX controls.
In plain wordsIn monkeys with removed ovaries, high-dose teriparatide increased spongy bone volume versus untreated OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck trabecular bone volume
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
The femoral neck showed significant reduction in trabecular bone volume (BV/TV) for OVX compared with sham, whereas PTH1 BV/TV was restored to sham levels and PTH5 BV/TV was greater than sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585003
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, trabecular bone volume after teriparatide withdrawal was intermediate between sham and OVX controls.
In plain wordsIn monkeys, spongy bone volume after teriparatide withdrawal was between sham and untreated OVX control levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedTrabecular bone volume after withdrawal
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Sham and OVX controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 12 months followed by 6 months withdrawalAs given in this study (monkeys).
Source sentences
Summary
The withdrawal groups had BV/TVs intermediate between sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585004
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, low-dose teriparatide increased trabecular number versus OVX controls.
In plain wordsIn monkeys with removed ovaries, low-dose teriparatide increased bone strut numbers versus untreated OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular number
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
PTH1 had trabecular number (Tb.N) greater than OVX, and PTH5 Tb.N was greater than sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585005
06AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, high-dose teriparatide increased trabecular number above sham controls.
In plain wordsIn monkeys with removed ovaries, high-dose teriparatide increased bone strut numbers above sham control levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular number
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Sham vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
PTH1 had trabecular number (Tb.N) greater than OVX, and PTH5 Tb.N was greater than sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585006
07AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, high-dose teriparatide increased trabecular number versus OVX controls.
In plain wordsIn monkeys with removed ovaries, high-dose teriparatide increased bone strut numbers versus untreated OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular number
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
PTH1 had trabecular number (Tb.N) greater than OVX, and PTH5 Tb.N was greater than sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585007
08AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, trabecular number after teriparatide withdrawal was intermediate between sham and OVX controls.
In plain wordsIn monkeys, bone strut numbers after teriparatide withdrawal were between sham and untreated OVX control levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedTrabecular number after withdrawal
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Sham and OVX controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 12 months followed by 6 months withdrawalAs given in this study (monkeys).
Source sentences
Summary
The withdrawal groups had Tb.Ns intermediate between sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585008
09AnimalAnimal study (in vivo)Efficacy outcome
In monkeys, trabecular orientation did not differ between teriparatide and other study groups.
In plain wordsIn monkeys, bone strut orientation did not differ between teriparatide and other study groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTrabecular orientation
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Other study groups
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 18 months or 12 months followed by 6 months withdrawalAs given in this study (monkeys).
Source sentences
Summary
No differences between groups were observed for trabecular orientation or trabecular thickness.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585009
10AnimalAnimal study (in vivo)Efficacy outcome
In monkeys, trabecular thickness did not differ between teriparatide and other study groups.
In plain wordsIn monkeys, bone strut thickness did not differ between teriparatide and other study groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTrabecular thickness
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Other study groups
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 18 months or 12 months followed by 6 months withdrawalAs given in this study (monkeys).
Source sentences
Summary
No differences between groups were observed for trabecular orientation or trabecular thickness.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585010
11AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, teriparatide increased femoral neck bone formation rate dose-dependently.
In plain wordsIn monkeys with removed ovaries, teriparatide increased bone formation rate with increasing dose.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation rate
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
Teriparatide dose-dependently increased bone formation rate and activation frequency in the femoral neck.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585011
12AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, teriparatide increased femoral neck activation frequency dose-dependently.
In plain wordsIn monkeys with removed ovaries, teriparatide increased the frequency of bone remodeling activation with increasing dose.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseActivation frequency
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
Teriparatide dose-dependently increased bone formation rate and activation frequency in the femoral neck.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585012
13AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, teriparatide tended to reduce marrow adipocyte number versus OVX controls.
In plain wordsIn monkeys with removed ovaries, teriparatide tended to reduce marrow fat cell numbers versus untreated OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseMarrow adipocyte number
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
whereas PTH tended to reduce adipocyte number and increase osteoblast number compared with OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585013
14AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, teriparatide tended to increase osteoblast number versus OVX controls.
In plain wordsIn monkeys with removed ovaries, teriparatide tended to increase bone-forming cell numbers versus untreated OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMarrow osteoblast number
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
whereas PTH tended to reduce adipocyte number and increase osteoblast number compared with OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585014
15AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, teriparatide increased cortical porosity dose-dependently.
In plain wordsIn monkeys with removed ovaries, teriparatide increased pores in outer bone with increasing dose.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical porosity
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
Analyses of the cortex showed dose-dependent elevation of cortical porosity, which was consistent with enhanced bone turnover with treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585015
16AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, cortical porosity after low-dose teriparatide withdrawal was lower than in OVX controls.
In plain wordsIn monkeys, outer bone had fewer pores after low-dose teriparatide withdrawal than in untreated OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCortical porosity after low-dose withdrawal
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/kg/day · 12 months followed by 6 months withdrawalAs given in this study (monkeys).
Source sentences
Summary
Cortical porosity was reduced after withdrawal of teriparatide, because PTH1W cortical porosity was lower than OVX, whereas PTH5W cortical porosity was intermediate between sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585016
17AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, cortical porosity after high-dose teriparatide withdrawal was intermediate between sham and OVX controls.
In plain wordsIn monkeys, bone porosity after high-dose teriparatide withdrawal was between sham and untreated OVX control levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedCortical porosity after high-dose withdrawal
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Sham and OVX controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/day · 12 months followed by 6 months withdrawalAs given in this study (monkeys).
Source sentences
Summary
Cortical porosity was reduced after withdrawal of teriparatide, because PTH1W cortical porosity was lower than OVX, whereas PTH5W cortical porosity was intermediate between sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585017
18AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, low-dose teriparatide increased proximal femur strength versus OVX controls.
In plain wordsIn monkeys with removed ovaries, low-dose teriparatide strengthened the upper thigh bone versus untreated OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProximal femur strength
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
Biomechanics showed that ovariectomy weakened proximal femora compared with sham, but PTH1, PTH5, and PTH1W were stronger than OVX and not different from sham.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585018
19AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, high-dose teriparatide increased proximal femur strength versus OVX controls.
In plain wordsIn monkeys with removed ovaries, high-dose teriparatide strengthened the upper thigh bone versus untreated OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProximal femur strength
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
Biomechanics showed that ovariectomy weakened proximal femora compared with sham, but PTH1, PTH5, and PTH1W were stronger than OVX and not different from sham.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585019
20AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, proximal femora remained stronger after low-dose teriparatide withdrawal than in OVX controls.
In plain wordsIn monkeys, upper thigh bones remained stronger after low-dose teriparatide withdrawal than in untreated OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProximal femur strength after low-dose withdrawal
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/kg/day · 12 months followed by 6 months withdrawalAs given in this study (monkeys).
Source sentences
Summary
Biomechanics showed that ovariectomy weakened proximal femora compared with sham, but PTH1, PTH5, and PTH1W were stronger than OVX and not different from sham.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585020
21AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, proximal femur strength with low-dose teriparatide did not differ from sham controls.
In plain wordsIn monkeys, upper thigh bone strength with low-dose teriparatide did not differ from sham controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeProximal femur strength
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Sham vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
Biomechanics showed that ovariectomy weakened proximal femora compared with sham, but PTH1, PTH5, and PTH1W were stronger than OVX and not different from sham.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585021
22AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, proximal femur strength with high-dose teriparatide did not differ from sham controls.
In plain wordsIn monkeys, upper thigh bone strength with high-dose teriparatide did not differ from sham controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeProximal femur strength
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Sham vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
Biomechanics showed that ovariectomy weakened proximal femora compared with sham, but PTH1, PTH5, and PTH1W were stronger than OVX and not different from sham.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585022
23AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, proximal femur strength after low-dose teriparatide withdrawal did not differ from sham controls.
In plain wordsIn monkeys, upper thigh bone strength after low-dose teriparatide withdrawal did not differ from sham controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeProximal femur strength after low-dose withdrawal
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Sham vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/kg/day · 12 months followed by 6 months withdrawalAs given in this study (monkeys).
Source sentences
Summary
Biomechanics showed that ovariectomy weakened proximal femora compared with sham, but PTH1, PTH5, and PTH1W were stronger than OVX and not different from sham.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585023
24AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, proximal femur strength after high-dose teriparatide withdrawal was intermediate between sham and OVX controls.
In plain wordsIn monkeys, upper thigh bone strength after high-dose teriparatide withdrawal was between sham and untreated OVX control levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedProximal femur strength after high-dose withdrawal
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
Sham and OVX controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/day · 12 months followed by 6 months withdrawalAs given in this study (monkeys).
Source sentences
Summary
PTH5W strength was intermediate between sham and OVX.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585024
25AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, teriparatide enhanced cortical area.
In plain wordsIn monkeys with removed ovaries, teriparatide increased outer bone area.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical area
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
Teriparatide enhancement of cortical area, cortical width, and trabecular bone volume seemed to more than compensate for the dose-dependent increase in cortical porosity.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585025
26AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, teriparatide enhanced cortical width.
In plain wordsIn monkeys with removed ovaries, teriparatide increased outer bone width.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical width
Study
monkeysn: not reported in source
Ovariectomized monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 and 5 microg/kg/day · 18 monthsAs given in this study (monkeys).
Source sentences
Summary
Teriparatide enhancement of cortical area, cortical width, and trabecular bone volume seemed to more than compensate for the dose-dependent increase in cortical porosity.
2 context sentences(design, population, supporting numbers)
Summary · context
Monkeys were treated with vehicle (sham or OVX controls), 1 microg/kg/day teriparatide [parathyroid hormone (1-34); PTH1], or 5 microg/kg/day teriparatide (PTH5) for 18 months or for 12 months followed by 6 months of treatment withdrawal (PTH1W and PTH5W, respectively).
Summary · context
Excised proximal femora were analyzed by microCT, conventional histomorphometry, and biomechanics.
Report a problemFND-1500585026

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.